Fairvalue-Calculator Fairvalue-Calculator
EN DE

Exagen Inc (XGN) Fair Value & Analysis

Healthcare · US · Market cap $109M

Price$4.64
Fair Value$3.75
Upside-19.2%
Quality95/100
Evidence: Low Range $2.44 – $4.59

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Exagen Inc (XGN) currently trades at $4.64, while our model-based Fair Value estimate is $3.75 — implying the stock looks roughly 19.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assess…

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -54% Danaher Corporation (DHR) -54% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -53% Lonza Group (LZAGY) -77% Agilent Technologies, Inc (A) -52%

Frequently asked questions

Is Exagen Inc (XGN) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $3.75 versus a price of $4.64 — about −19% (overvalued). Model-based estimate, not financial advice.
What is the fair value of XGN?
Our 21-model fair value for Exagen Inc is $3.75 (as of Jun 25, 2026), built from audited fundamentals. The current price is $4.64.
What is the quality score of XGN?
Exagen Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.